Sartorius Stedim Biotech (SSB) has announced it will combine technologies with US-based cell culture analysers Nova Biomedical, as a result of increased customer demand.
Dr Reddy’s will expand its biosimilar manufacturing capacity in Hyderabad by 4,000L using GE Healthcare’s FlexFactory platform based on single-use technologies.
A second single-use production line could offer commercial-scale capacity for bispecific antibodies but Glenmark says it would need to scale-up further to support more traditional biologics.
Pall Corporation, GE Healthcare and LEWA Process Technologies showed off their latest downstream offerings to Biopharma-Reporter in Amsterdam last week.
United BioPharma Inc. (UBP), with government backing, has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan.
European biotech companies Valneva and Bavarian Nordic have entered a commercial agreement to develop cell-based vaccines using production methods that are faster and cheaper than methods that use hen’s eggs.
BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.
Lonza's biopharma business grew faster than other divisions in 2016 with a drug firm becoming the Swiss life science supplier's biggest customer for the first time since 2013
GE Healthcare has completed another tech installation at FujiFilm Diosynth’s biopharmaceuticals facility in Billingham, UK, integrating a single-use purification system with bioreactors it provided in 2014.
Arven will use GE Healthcare’s FlexFactory manufacturing platform to increase capacity at its mammalian-cell based bioproduction facility in Kirklareli, Turkey.
The Novo Nordisk Foundation has awarded a DKK118m ($17m) grant to fund development of a fermentation pilot plant for cell line scale up experiments at the Technical University of Denmark.
GE Healthcare says a new inflatable bioreactor bag configured in perfusion mode can achieve a cell density over four times that of the current industry standard.
After buying two CMOs, Japanese glassmaker AGC has made “a full-fledged launch” into the biologics manufacturing space and says it will consider further M&A opportunities.
Merck has announced plans for process and cell line development centres in the US and China citing biopharmaceutical industry demand for integrated services.
GE Healthcare hopes to increase the yield of biopharmaceuticals made using its Chinese Hamster Ovary (CHO) expression system through a partnership with synthetic biology firm Synpromics.
Acticor Biotech has made a deal with Merck KGaA’s CMO MilliporeSigma to use its Provantage End-to-End services to make its anti-thrombotic antibody fragment ACT-017 for stroke.
Sanofi has teamed with JHL Biotech to develop biosimilar products, including a version of Rituxan (rituximab), for the Chinese and international markets.
The conservatism of the biotech industry held back adoption of continuous manufacturing tech but this is now changing says Novasep, winner of the CPhI bioprocessing award.
Sartorius Stedim Biotech (SSB) claims benchtop vaccine and protein purification techs could save developers €2000 per batch and reduce processing time by 60%.
European stand-alone guidelines for the manufacture of Advanced Therapy Medicine Product (ATMP) could lead to disparities in GMP standards, says the Alliance for Regenerative Medicine.
WuXi has responded to a global demand for perfusion technologies by opening a commercial scale manufacturing site in China with two 1,000L disposable bioreactors.
Jacobs Engineering Group has been contracted to collaborate with GE Healthcare on the development of Pfizer’s $350m monoclonal antibody manufacturing centre in Hangzhou, China.
Qualification documentation and manufacturing consistency can ease end-user fears of leachable contamination says GE Healthcare, which has developed a new single-use film with Sealed Air Corporation.
Novartis has recruited Jacobs to undertake a €100m expansion at a French biomanufacturing facility which will add a second purification line and several cell culture bioreactors.
As it enters a collaboration to develop environmentally sustainable yet low-cost vaccines, MilliporeSigma says pharma and regulators must look to next-generation technologies for future vaccine development.
Pfizer has struck a strategic partnership with GE Healthcare to construct and equip a biomanufacturing centre focused on producing biosimilars for China.
A new $60m facility at a MSD site in Ireland will offer Fujifilm Diosynth customers 20,000L of microbial biologics capacity in a collaboration between the two firms.
Single-use manufacturing runs have been limited to 2,000L, but CMC Biologics says it will be able to offer 12,000L of commercial scale through its bioreactor configuration platform.
Evercyte has teamed up with VTU Technology to develop cell culture media free from animal derived products, which the firm says is now essential for biomanufacturers.
EAG has further invested in ABC Laboratories' capacity and analytical capabilities in order to help meet demand for high-end biopharmaceutical analysis.
Lonza plans to expand mammalian cell culture-based drug and viral manufacturing capacity after growth in both businesses helped it to record first quarter sales.
Single-use is the future but stainless steel bioreactors will always play a role in drug production says an expert, who thinks firms could do worse than consult a CMO before deciding in which technology to invest.
